Clinical Trials Logo

Clinical Trial Summary

This is a single center, longitudinal cohort study in which subjects will receive 9-valent HPV vaccine according to package insert (i.e., one dose of 9-valent HPV vaccine on day (D) 0 followed by a second dose 2 months later and a third dose 6 months later). Immune responses in the blood, saliva, bone marrow, and lymph nodes will be assessed in subjects receiving the HPV vaccine. Blood samples for immunologic testing will be collected at screening (from D-60 to D-7), on D0 (before vaccination), D1, D7, D14, D30, D60 (before vaccination), D61, D67, D74, D90, D180 (before vaccination), D187, D194, D210, D365, and 730. Saliva samples for antibody testing will be collected on D0 (before vaccination), D30, D60 (before vaccination), D90, D180 (before vaccination), D210, D365, and D730. Axillary lymph node sampling by fine needle aspiration will be done in all groups at D-30 and 2 additional times in per group. Group 1 will have lymph node sampling done D14 and D30 after the first dose. Group 2 will have lymph node sampling done D74 and D90. Group 3 will have lymph node sampling D194 and D210. Bone marrow sampling will be done for all groups at D730.


Clinical Trial Description

Human papillomaviruses (HPV) cause cervical, anal, oropharyngeal, vulvar, vaginal, and penile cancers. There are over 200 types of HPV; 12 are known to cause cancer. The current HPV vaccine is a subunit vaccine, meaning it is made of only part of the virus (a protein) and cannot infect humans. The HPV vaccine is highly effective at preventing disease by HPV types that cause 90% of cancer cases and 90% of genital warts cases in women and men who do not have ongoing or prior HPV infection. Most vaccines protect by generating antibodies. Importantly, the HPV vaccine, first approved in 2006, has been shown to make high levels of antibodies against HPV that last for >10 years. The durability of HPV vaccine antibody levels is exceptional compared to other approved and experimental subunit vaccines whose antibody levels drop more rapidly. However, how the HPV vaccine - let alone any vaccine - generates long-lasting antibodies is not understood. Understanding how vaccines make high levels of long-lasting antibodies will help the efforts to successfully and reliably design new vaccines that make these highly desired responses (like vaccines against new pandemics). The investigators designed this study to better understand how the HPV vaccine generates such high levels of long-lasting antibodies in humans. To do this, they need to study early immune responses in lymph nodes, which is where cells that make antibodies (B cells) are activated by the vaccine. They will also need to study immune responses in blood. For example, to measure the levels of antibodies in blood and also the levels of cells that help B cells (helper T cells). As the HPV vaccine can protect against oropharyngeal cancer, the study team aim to understand the level of antibodies in the saliva and how they compare to blood. Finally, antibodies themselves are not long-lived as proteins, but the cells that make these antibodies are (specialized B cells called plasma cells). Plasma cells are found in the bone marrow. It is important that the research team find and study these cells making antibodies against HPV, so they can better understand how they contribute to long-lasting antibody levels. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05031078
Study type Interventional
Source Emory University
Contact Erin Scherer, Ph.D.
Phone 404-712-6904
Email [email protected]
Status Not yet recruiting
Phase Phase 4
Start date September 2021
Completion date September 2024

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05006833 - Text and Talk: A Multi-level Intervention to Increase Provider HPV Vaccine Recommendation Effectiveness N/A
Completed NCT01105000 - Human Papilloma Virus (HPV) Knowledge and Attitudes and the Role of (SES) Socioeconomic Status and Ethnicity
Completed NCT03082950 - HPV Infections, Cancer of the Vulva and Therapeutical Success
Recruiting NCT01512784 - Long Term Immunogenicity of Quadrivalent Human Papillomavirus Vaccine (Gardasil®)in HIV-infected Adolescents and Young Adults Phase 3
Completed NCT01231945 - Low-Cost Molecular Cervical Cancer Screening Study N/A
Completed NCT02247999 - Improving Cervical Cancer Screening Among HIV-Infected Women in India
Terminated NCT01468636 - A RTC to Examine the Effectiveness of 400 mg of Oral Zinc Gluconate as Adjunctive Therapy for Ano-genital Warts Phase 4
Recruiting NCT04965792 - Post-treatment Surveillance in HPV+ Oropharyngeal SCC
Completed NCT01101750 - Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls? Phase 4
Completed NCT00730704 - Acceptance of Human Papillomavirus Vaccination in Postpartum Women N/A
Recruiting NCT01011712 - The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise
Recruiting NCT04064515 - CTCs in Cervix Cancer
Recruiting NCT04607850 - Prime-boost Vaccine Study in Women With Low-grade Cervical HPV Lesions Phase 1/Phase 2
Completed NCT04909814 - Colposcopic Impression in a Birth Cohort Previously Eligible for HPV-vaccination
Not yet recruiting NCT04859530 - Automated Cervical Cancer Screening Using a Smartphone-based Artificial Intelligence Classifier N/A
Completed NCT00680147 - Human Papillomavirus (HPV) Vaccination Acceptance by African-American Parents: Identifying Psychosocial Barriers Phase 2
Recruiting NCT04974619 - Adaptation Of An HPV Education Resource To Promote HPV Vaccination
Completed NCT00342511 - Pilots of Self-Collection for HPV DNA Detection N/A
Recruiting NCT04591977 - Self-Sampling for Human Papillomavirus (HPV) at Well Women Appointments N/A
Recruiting NCT03000998 - Web App Technology for Boys and Parents: Improving HPV Vaccine Uptake N/A